Objective: To document the impact on patient-reported outcomes and health-related quality of life (HRQoL) of treatment with imiquimod cream in patients with actinic keratosis (AK) and superficial basal cell carcinoma (sBCC). Methods: This open-label, multicenter study included AK and sBCC patients eligible for treatment with imiquimod 5% cream. HRQoL was measured by the Skindex-17 and the Skin Cancer Index (SCI) and treatment satisfaction by the Treatment Satisfaction Questionnaire for Medication. Results: 118 AK patients and 84 patients with sBCC were included. Low baseline HRQoL impairment was found on both questionnaires, which remained low after treatment, except for a small dip at the end of the application period. Conclusion: Imiquimod 5% cream treatment has no clinically relevant HRQoL impact in AK and sBCC patients according to the Skindex-17 and SCI. The effect of imiquimod treatment on HRQoL may be limited or these questionnaires do not fully capture relevant issues, such as fear of recurrence.

Additional Metadata
Keywords Actinic keratosis, Health-related quality of life, Imiquimod, Patient-reported outcomes, Superficial basal cell carcinoma, Treatment satisfaction
Persistent URL dx.doi.org/10.1159/000381420, hdl.handle.net/1765/83012
Journal Dermatology: international journal for clinical and investigative dermatology
Waalboer Spuij, R, Holterhues, C, van Hattem, S, Schuttelaar, M.L.A, Gaastra, M.T.W, Kuijpers, D.I.M, … Nijsten, T.E.C. (2015). Patient Perception of Imiquimod Treatment for Actinic Keratosis and Superficial Basal Cell Carcinoma in 202 Patients. Dermatology: international journal for clinical and investigative dermatology, 231(1), 56–62. doi:10.1159/000381420